Comera Life Sciences (CMRA) 10-Q 12 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 11, 2023
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	1-41403
Entity Registrant Name	Comera Life Sciences Holdings, Inc.
Entity Central Index Key	0001907685
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-4706968
Entity Address, Address Line One	12 Gill Street
Entity Address, Address Line Two	Suite 4650
Entity Address, City or Town	Woburn
Entity Address, Postal Zip Code	01801
Entity Address, State or Province	MA
City Area Code	617
Local Phone Number	871-2101
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		22,305,138
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	CMRA
Security Exchange Name	NASDAQ
Warrants
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	CMRAW
Security Exchange Name	NASDAQ

Consolidated Balance sheets (Un

Consolidated Balance sheets (Unaudited) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,538,653	$ 446,607
Restricted cash - current		1,505,625
Accounts receivable		34,320
Deferred issuance costs		90,047
Prepaid expenses and other current assets	868,784	986,499
Total current assets	2,407,437	3,063,098
Restricted cash - non-current	50,000	50,000
Property and equipment, net	234,576	257,186
Right of use asset	263,904	313,629
Security deposit	43,200	43,200
Total assets	2,999,117	3,727,113
Current liabilities:
Accounts payable	1,772,187	1,458,267
Accrued expenses and other current liabilities	1,365,334	1,295,764
Insurance premium financing		455,562
Deposit liability		1,505,625
Deferred revenue		144,280
Lease liability - current	217,500	199,184
Total current liabilities	3,355,021	5,058,682
Derivative warrant liabilities	250,745	277,507
Lease liability - noncurrent	53,669	120,302
Total liabilities	3,659,435	5,456,491
Commitments and contingencies (Note 15)
Stockholders' equity (deficit):
Common stock, $0.0001 par value; 150,000,000 shares authorized; 19,152,693 and 16,709,221 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	1,915	1,671
Additional paid-in capital	32,118,476	28,655,164
Accumulated deficit	(37,385,235)	(34,903,923)
Total stockholders' deficit	(5,264,844)	(6,247,088)
Total liabilities, convertible preferred stock and stockholders' deficit	2,999,117	3,727,113
Series A Convertible Preferred Stock
Current liabilities:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; 4,305 shares designated Series A convertible preferred stock; 4,305 shares issued and outstanding at March 31, 2023 and December 31, 2022	$ 4,604,526	$ 4,517,710

Consolidated Balance sheets (_2

Consolidated Balance sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	19,152,693	16,709,221
Common Stock, Shares, Outstanding	19,152,693	16,709,221
Convertible preferred stock, par value	$ 0.0001
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Series A Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	4,305	4,305
Convertible preferred stock, shares issued	4,305	4,305
Convertible preferred stock, shares outstanding	4,305	4,305

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 392,915	$ 95,334
Cost of revenue	116,519	44,524
Operating expenses:
Research and development	343,705	487,217
General and administrative	2,433,147	2,016,245
Total operating expenses	2,776,852	2,503,462
Loss from operations	(2,500,456)	(2,452,652)
Other income (expense), net:
Change in fair value of derivative warrant liabilities	26,762
Interest expense	(7,618)	(77)
Other expense, net		(426,666)
Total other income (expense), net	19,144	(426,743)
Net loss and comprehensive loss	(2,481,312)	(2,879,395)
Less: accretion of convertible preferred stock to redemption value	(86,816)
Net loss attributable to common stockholders	$ (2,568,128)	$ (2,879,395)
Net loss per share attributable to common stockholders - basic	$ (0.13)	$ (4.01)
Net loss per share attributable to common stockholders - diluted	$ (0.13)	$ (4.01)
Weighted-average number of common shares used in computing net loss per share attributable to common stockholders - basic	19,033,436	718,419
Weighted-average number of common shares used in computing net loss per share attributable to common stockholders - diluted	19,033,436	718,419

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($)	Total	January 2023 PIPE	Arena purchase agreement	Series A Convertible Preferred Stock	Convertible Preferred Stock	Common Stock	Common Stock January 2023 PIPE	Common Stock Arena purchase agreement	Additional Paid-in Capital	Additional Paid-in Capital January 2023 PIPE	Additional Paid-in Capital Arena purchase agreement	Accumulated Deficit
Beginning Balance at Dec. 31, 2021					$ 20,857,453
Beginning Balance, Shares at Dec. 31, 2021					13,802,758
Beginning Balance at Dec. 31, 2021	$ (14,686,247)					$ 31			$ 2,213,547			$ (16,899,825)
Beginning Balance, Shares at Dec. 31, 2021						308,443
Issuance of common stock upon exercise of stock options	429,430					$ 74			429,356
Common stock exercised						735,859
Stock-based compensation expense	42,556								42,556
Net loss	(2,879,395)											(2,879,395)
Ending Balance at Mar. 31, 2022					$ 20,857,453
Ending Balance, Shares at Mar. 31, 2022					13,802,758
Ending Balance at Mar. 31, 2022	(17,093,656)					$ 105			2,685,459			(19,779,220)
Ending Balance, Shares at Mar. 31, 2022						1,044,302
Beginning Balance at Dec. 31, 2022				$ 4,517,710
Beginning Balance, Shares at Dec. 31, 2022				4,305
Beginning Balance at Dec. 31, 2022	(6,247,088)					$ 1,671			28,655,164			(34,903,923)
Beginning Balance, Shares at Dec. 31, 2022						16,709,221
Issuance of common stock		$ 3,200,449	$ 49,158				$ 240	$ 4		$ 3,200,209	$ 49,154
Issuance of common stock, shares							2,406,242	37,230
Accretion of convertible preferred stock to redemption value				$ 86,816
Accretion of convertible preferred stock to redemption value	(86,816)								(86,816)
Stock-based compensation expense	300,765								300,765
Net loss	(2,481,312)											(2,481,312)
Ending Balance at Mar. 31, 2023				$ 4,604,526
Ending Balance, Shares at Mar. 31, 2023				4,305
Ending Balance at Mar. 31, 2023	$ (5,264,844)					$ 1,915			$ 32,118,476			$ (37,385,235)
Ending Balance, Shares at Mar. 31, 2023						19,152,693

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (2,481,312)	$ (2,879,395)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	300,765	42,556
Depreciation expense	28,260	24,774
Noncash lease expense	1,408	(268)
Change in fair value of derivative warrant liabilities	(26,762)
Changes in operating assets and liabilities:
Accounts receivable	34,320	(148,000)
Prepaid expenses and other current assets	117,715	220,676
Due from related parties		121
Accounts payable	126,423	123,024
Accrued expenses and other current liabilities	137,695	(300,767)
Deferred revenue	(144,280)	47,727
Net cash used in operating activities	(1,905,768)	(2,869,552)
Cash flows from investing activities:
Purchases of property and equipment	(88,359)
Net cash flows used in investing activities	(88,359)
Cash flows from financing activities:
Deferred offering costs paid in cash		(206,917)
Proceeds from January 2023 PIPE, net of issuance costs	1,986,952
Proceeds from the Arena Purchase Agreement	49,158
Repayment of insurance premium financing	(455,562)
Proceeds from exercise of stock options		429,430
Net cash provided by financing activities	1,580,548	222,513
Net decrease in cash, cash equivalents and restricted cash	(413,579)	(2,647,039)
Cash, cash equivalents and restricted cash at beginning of period	2,002,232	6,560,140
Cash, cash equivalents, and restricted cash at end of period	1,588,653	3,913,101
Supplemental information:
Cash and cash equivalents	1,538,653	3,863,101
Restricted cash	50,000	50,000
Total cash, cash equivalents, and restricted cash shown in statements of cash flows	1,588,653	3,913,101
Supplemental disclosure of noncash investing and financing activities:
Fixed asset additions in accounts payable	5,650
Stock issuance costs in accounts payable and accrued expenses and other current liabilities	360,253	$ 109,738
Issuance of common stock in exchange for services by the Company's Board of Directors	68,125
Accretion on convertible preferred stock	$ 86,816

Organization

Organization	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Formation and Organization Comera Life Sciences Holdings, Inc. (“CLS Holdings,” “Comera” or the “Company” ) was incorporated in Delaware on January 25, 2022 as a wholly-owned subsidiary of Comera Life Sciences, Inc. ( “Legacy Comera”) for the purpose of effecting the Transaction (as defined below). Legacy Comera was formed in the state of Delaware on January 2, 2014 as ReForm Biologics, LLC. On April 30, 2021, Legacy Comera completed a corporate reorganization (the “Reorganization”) and changed its name to ReForm Biologics, Inc. As part of the Reorganization, each issued and outstanding capital unit of Legacy Comera as of the date of the Reorganization was exchanged for shares of convertible preferred stock of Legacy Comera and previously outstanding incentive units of Legacy Comera were cancelled. On January 7, 2022, Legacy Comera changed its name to Comera Life Sciences, Inc. to emphasize Comera’s vision of a compassionate new era in medicine. On May 19, 2022, in connection with the closing of the Transaction, Legacy Comera became a wholly-owned subsidiary of CLS Holdings. Comera is a biotechnology company dedicated to promoting a compassionate new era in medicine. The Company applies a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (“IV”) to subcutaneous (“SQ”) forms. This revolutionary technology provides patients and families with the freedom of self-injectable care, allowing them to realize the potential of these life changing therapies, and to unlock the vast potential of their own lives. To accomplish this, Comera is developing an internal portfolio of proprietary therapeutics that incorporate Comera’s innovative proprietary formulation platform, SQore ™ . Comera also collaborates with pharmaceutical and biotechnology companies, applying the SQore ™ platform to Comera’s partners’ biologic medicines to deliver enhanced formulations that facilitate self-injectable care. Transaction On May 19, 2022 (the “Closing Date”), the Company consummated the acquisition of all of the issued and outstanding shares of OTR Acquisition Corp. (“OTR”) and Legacy Comera (the “Transaction”), in accordance with the Business Combination Agreement dated January 31, 2022 (as amended on May 19, 2022, the “Business Combination Agreement”) by and among the Company, Legacy Comera, OTR, CLS Sub Merger 1 Corp., a Delaware corporation, (“Comera Merger Sub”), and CLS Sub Merger 2 Corp., a Delaware corporation (“OTR Merger Sub”). Pursuant to the terms of the Business Combination Agreement, a transaction between OTR and Legacy Comera was effected through the merger of Comera Merger Sub with and into Legacy Comera, with Legacy Comera surviving the merger as a wholly-owned subsidiary of CLS Holdings, and through a merger of OTR Merger Sub with and into OTR, with OTR surviving the merger as a wholly-owned subsidiary of CLS Holdings. OTR was formed in the state of Delaware for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The Transaction was accounted for as a reverse recapitalization because Legacy Comera has been determined to be the accounting acquirer. Under the reverse recapitalization model, the Transaction treated Legacy Comera as issuing equity for the net assets of OTR, with no goodwill or intangible assets recorded.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The condensed consolidated financial statements do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s consolidated financial statements and related notes for the years ended December 31, 2022 and 2021 included in the Form 10-K filed with the SEC on March 17, 2023 (the “2022 Annual Report”). The financial information as of March 31, 2023, and for the three months ended March 31, 2023 and 2022, is unaudited. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for the fair presentation of financial position, results of operations, and cash flows at the dates and for the periods presented, have been included. The balance sheet data as of December 31, 2022 was derived from audited consolidated financial statements. The results of the Company’s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year. Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Significant discovery, research and development efforts, including clinical testing and regulatory approval, are required prior to commercialization of any potential product candidates. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. Through March 31, 2023, the Company has funded its operations primarily with proceeds from the issuance of equity instruments and convertible notes. The Company has incurred recurring losses since its inception, including a net loss of $ 2.5 million and $ 2.9 million for the three months ended March 31, 2023 and 2022, respectively. In addition, as of March 31, 2023, the Company had an accumulated deficit of $ 37.4 million . The Company expects to continue to generate operating losses for the near future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company does not believe the cash, cash equivalents, and restricted cash on hand as of March 31, 2023 of $ 1.6 million will be sufficient to fund its operations and capital expenditure requirements for the next twelve months from the date the condensed consolidated financial statements are issued. The Company will be required to raise additional capital to continue to fund its operations. Such funding may not be available on acceptable terms, or at all. If the Company is unable to access additional funds when needed, it may not be able to continue operations or the Company may be required to delay, scale back or eliminate some or all of its ongoing research and development efforts and other operations. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm its business, financial condition and results of operations. These uncertainties create substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of derivative warrant liabilities, valuation of earn-out shares, and revenue recognition. Changes in estimates are recorded in the period in which they become known. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. Summary of Significant Accounting Policies The significant accounting policies of the Company are set forth in Note 2, Basis of Presentation and Significant Accounting Policies , of the consolidated financial statements included in the 2022 Annual Report. During the three months ended March 31, 2023, the Company did not make any changes to its significant accounting policies. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements and disclosures.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities	3. Fair Value of Financial Assets and Liabilities The following table presents the Company’s fair value hierarchy for its liabilities, which are measured at fair value on a recurring basis as of March 31, 2023: Fair Value Measurements at March 31, 2023 Using: Level 1 Level 2 Level 3 Total Liabilities: Derivative warrant liabilities $ — $ 250,745 $ — $ 250,745 Fair Value Measurements at December 31, 2022 Using: Level 1 Level 2 Level 3 Total Liabilities: Derivative warrant liabilities $ — $ 277,507 $ — $ 277,507 There were no assets for which fair value was required to be disclosed as of March 31, 2023 or December 31, 2022. During the three months ended March 31, 2023 , there were no transfers between Level 1, Level 2 and Level 3.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: March 31, December 31, Prepaid insurance $ 535,098 $ 913,611 Contract assets 248,635 — Other 85,051 72,888 Prepaid expenses and other current assets $ 868,784 $ 986,499

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, Net Property and equipment, net consisted of the following: March 31, December 31, Lab equipment $ 676,010 $ 587,650 Leasehold improvements 36,149 36,149 Computer equipment 35,002 32,178 Other equipment 9,411 9,411 Construction in progress 2,825 88,359 759,397 753,747 Less accumulated depreciation ( 524,821 ) ( 496,561 ) Property and equipment, net $ 234,576 $ 257,186 Depreciation expense for the three months ended March 31, 2023 and 2022 was $ 28 thousand and $ 25 thousand, respectively.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: March 31, December 31, Accrued bonus $ 882,485 $ 767,093 Professional fees 274,766 282,454 Accrued vacation 30,814 21,194 Other 177,269 225,023 Accrued expenses and other current liabilities $ 1,365,334 $ 1,295,764

Insurance Premium Financing

Insurance Premium Financing	3 Months Ended
	Mar. 31, 2023
Insurance Premium Financing [Abstract]
Insurance Premium Financing	7. Insurance Premium Financing In May 2022, the Company entered into a finance agreement with First Insurance Funding in order to fund a portion of its insurance policies. The amount financed was $ 1.5 million and incurred interest at a rate of 4.00 %. The Company was required to make monthly payments of $ 154 thousand through March 2023 . There is no outstanding balance as of March 31, 2023 .

Legacy Comera Convertible Prefe

Legacy Comera Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2023
Temporary Equity [Line Items]
Convertible Preferred Stock	8. Convertible Preferred Stock As of March 31, 2023 , the Company’s amended and restated certificate of incorporation (the “Articles”) provides for a class of authorized stock known as preferred stock, consisting of 1,000,000 shares, $ 0.0001 par value per share, issuable from time to time in one or more series. In connection with the Transaction, a certificate of designation was filed to designate and authorize the issuance of up to 4,305 shares of Series A Convertible Preferred Stock, par value $ 0.0001 per share (“Series A Preferred Stock”). Convertible preferred stock consisted of the following as of March 31, 2023: Par Value Shares Authorized Shares Issued and Carrying Value Liquidation Common Stock Series A Preferred Stock $ 0.0001 4,305 4,305 $ 4,604,526 $ 4,604,526 342,754 In May 2022, the Company issued 4,305 shares of Series A Preferred Stock. The Series A Preferred Stock was issued in connection with the Transaction and the Settlement and Release Agreement (“Settlement Agreement”) in settlement of $ 4.3 million of advisory fees owed to Maxim Group LLC (“Maxim”) with an original purchase price of $ 1,000 per share (the “Series A Original Purchase Price”). The Company incurred $ 162 thousand of issuance costs in connection with the Series A Preferred Stock. The holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to the declaration or payment of any dividend on any other currently-outstanding capital stock, dividends when, as and if declared by the board of directors, payable quarterly on January 1, April 1, July 1 and October 1 of each calendar year (each date a “Series A Quarterly Dividend Payment Date”), commencing on and including July 1, 2022, which dividends shall be paid in cash at a rate of 8.0% per annum on the Series A Original Purchase Price for the first six Series A Quarterly Dividend Payment Dates, which shall increase by 2% per annum from and after each successive Series A Quarterly Dividend Payment Date, up to a maximum of 18%. Such dividends shall cumulate quarterly at the Series A Dividend Rate if not declared and paid on a Series A Quarterly Dividend Payment Date. As of March 31, 2023 , no cash dividends have been declared or paid and the Company has $ 300 thousand of cumulative dividends in arrears. As the preferred stock is considered to be contingently redeemable, the preferred stock has been classified outside of permanent equity. Since the contingent redemption is considered probable, the Series A Preferred Stock will be accreted to its redemption value at each reporting date. The Company recorded accretion of $ 87 thousand during the three months ended March 31, 2023 , which is considered a deemed dividend.

Convertible Preferred Stock

Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2023
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	8. Convertible Preferred Stock As of March 31, 2023 , the Company’s amended and restated certificate of incorporation (the “Articles”) provides for a class of authorized stock known as preferred stock, consisting of 1,000,000 shares, $ 0.0001 par value per share, issuable from time to time in one or more series. In connection with the Transaction, a certificate of designation was filed to designate and authorize the issuance of up to 4,305 shares of Series A Convertible Preferred Stock, par value $ 0.0001 per share (“Series A Preferred Stock”). Convertible preferred stock consisted of the following as of March 31, 2023: Par Value Shares Authorized Shares Issued and Carrying Value Liquidation Common Stock Series A Preferred Stock $ 0.0001 4,305 4,305 $ 4,604,526 $ 4,604,526 342,754 In May 2022, the Company issued 4,305 shares of Series A Preferred Stock. The Series A Preferred Stock was issued in connection with the Transaction and the Settlement and Release Agreement (“Settlement Agreement”) in settlement of $ 4.3 million of advisory fees owed to Maxim Group LLC (“Maxim”) with an original purchase price of $ 1,000 per share (the “Series A Original Purchase Price”). The Company incurred $ 162 thousand of issuance costs in connection with the Series A Preferred Stock. The holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to the declaration or payment of any dividend on any other currently-outstanding capital stock, dividends when, as and if declared by the board of directors, payable quarterly on January 1, April 1, July 1 and October 1 of each calendar year (each date a “Series A Quarterly Dividend Payment Date”), commencing on and including July 1, 2022, which dividends shall be paid in cash at a rate of 8.0% per annum on the Series A Original Purchase Price for the first six Series A Quarterly Dividend Payment Dates, which shall increase by 2% per annum from and after each successive Series A Quarterly Dividend Payment Date, up to a maximum of 18%. Such dividends shall cumulate quarterly at the Series A Dividend Rate if not declared and paid on a Series A Quarterly Dividend Payment Date. As of March 31, 2023 , no cash dividends have been declared or paid and the Company has $ 300 thousand of cumulative dividends in arrears. As the preferred stock is considered to be contingently redeemable, the preferred stock has been classified outside of permanent equity. Since the contingent redemption is considered probable, the Series A Preferred Stock will be accreted to its redemption value at each reporting date. The Company recorded accretion of $ 87 thousand during the three months ended March 31, 2023 , which is considered a deemed dividend.

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Common Stock	. Common Stock As of March 31, 2023 , the authorized capital stock of the Company included 150,000,000 shares of common stock, $ 0.0001 par value per share. The voting, dividend and liquidation rights of the holders of the Company’s common stock are subject to and qualified by the rights, powers and preferences of the holders of the Series A Preferred Stock. Each share of common stock entitles the holder to one vote , together with the holders of the preferred stock on an as converted to common stock basis, on all matters submitted to the stockholders for a vote. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of the preferred stock. Through March 31, 2023 , no cash dividends have been declared or paid. As of March 31, 2023, the Company has reserved the following shares of common stock for future issuance: Exercise of outstanding stock options 2,516,734 Available for issuance under equity compensation plans 487,473 Exercise of outstanding common stock warrants 15,853,816 Conversion of Series A Preferred Stock 1,028,262 Reserved for issuance pursuant to the Arena Purchase Agreement 4,204,644 Total shares of authorized common stock reserved for future issuance 24,090,929 January 2023 PIPE On January 2, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with a select group of existing shareholders and members of the Company's board of directors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “January 2023 PIPE”) an aggregate of 2,406,242 units (collectively, the “Units”), each Unit consisting of (i) one share of common stock, and (ii) one warrant (the “January 2023 PIPE Warrants”) to purchase two shares of common stock (the “Warrant Shares”) at an exercise price of $ 1.23 per Warrant Share, for an aggregate purchase price of approximately $ 3.6 million, consisting of $ 1.48 per Unit, inclusive of $ 0.25 per 2023 PIPE Warrant. The financing closed on January 4, 2023 (the “January 2023 PIPE”), resulting in net proceeds of $ 3.2 million, after deducting offering costs of $ 361 thousand. The following table reconciles the gross proceeds received from the January 2023 PIPE to the statement of cash flows: Total gross proceeds 3,561,238 Advanced deposits received in FY22 ( 1,505,625 ) Non-cash proceeds related to board compensation ( 68,125 ) Issuance costs paid in cash ( 536 ) FY23 cash proceeds from January 2023 PIPE, net of issuance costs 1,986,952 Common Stock Purchase Agreement On August 31, 2022, the Company entered into a purchase agreement (the “Arena Purchase Agreement”) with Arena Business Solutions Global SPC II, Ltd. (“Arena”), pursuant to which Arena has committed to purchase up to $ 15.0 million (the “Commitment Amount”) of the Company’s common stock, subject to an increase, at the Company's option, to $ 30.0 million of the Company's common stock (the “Additional Commitment Amount”). Under the terms and subject to the conditions of the Arena Purchase Agreement, the Company has the right, but not the obligation, to sell to Arena, and Arena is obligated to purchase up to $ 15.0 million of the Company’s common stock, subject to increase at the Company's option by the Additional Commitment Amount. Such sales of common stock by the Company will be subject to certain limitations, and may occur from time to time, at the Company’s sole discretion, over the approximately 36-month period commencing on the date of the Purchase Agreement, provided that the registration statement (the “Registration Statement”) covering the resale by Arena of the shares of the Company’s common stock purchased under the Purchase Agreement remains effective, and the other conditions set forth in the Arena Purchase Agreement are satisfied. The purchase price of the shares of the Company’s common stock will be equal to 96 % of the simple average of the daily VWAP of the Company’s common stock immediately preceding the time of sale as computed under the Arena Purchase Agreement. The Company determined that its right to sell shares of the Company’s common stock to Arena represents a freestanding put option under ASC 815, but has a fair value of zero, and therefore no additional accounting was required. The Company issued 296,181 shares of common stock (the “Commitment Shares”) to Arena as a commitment fee in connection with entering into the Purchase Agreement. The $ 650 thousand fair value of the Commitment Shares along with $ 379 thousand of other issuance costs related to the Purchase Agreement were recognized as a loss within other expense, net in the year ended December 31, 2022. During the three months ended March 31, 2023 , the Company sold 37,230 shares of common stock at a weighted-average price of $ 1.32 per share, resulting in net proceeds of $ 49 thousand.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-Based Compensation	10. Stock-Based Compensation 2021 Stock Option and Grant Plan On April 30, 2021, Legacy Comera established the 2021 Stock Option and Grant Plan (the “2021 Plan”), which provided for the grant of incentive stock options, non-statutory stock options, restricted stock awards, unrestricted stock awards and restricted stock units. In connection with the closing of the Transaction, option awards outstanding under the 2021 Plan were exchanged for options to purchase shares of the Company's common stock (the “Exchanged Options”), with proportional adjustments to the number of shares underlying the options and the exercise price of the options approved by the compensation committee and board of directors of Legacy Comera. Other than with respect to the exercise price and the underlying number of shares of the Company's common stock, the Exchanged Options remain subject to the terms and conditions of the Legacy Comera option awards issued pursuant to the 2021 Plan. The Exchanged Options are outstanding under and count against the number of shares reserved for issuance pursuant to the 2022 Equity and Incentive Plan (the “2022 Plan”). Following the closing of the Transaction, no additional awards may be granted under the 2021 Plan. As of March 31, 2023 , there were 2,516,734 options outstanding, inclusive of 1,159,934 Exchanged Options, exercisable for 1,159,934 shares of common stock at a weighted-average exercise price of $ 0.59 per share. 2022 Equity and Incentive Plan On May 10, 2022, the Company established the 2022 Plan, which provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, unrestricted stock awards, restricted stock units, stock appreciation rights, cash awards and dividend equivalent rights. Incentive stock options may be granted only to the Company’s employees, including officers. Non-statutory options, restricted stock awards, unrestricted stock awards, restricted stock units, stock appreciation rights, cash awards and dividend equivalent rights may be granted to employees, directors, consultants and key persons of the Company. The total number of common shares authorized to be issued under the 2022 Plan was 2,059,838 . The share pool will automatically increase on January 1 of each year by four percent of the number of shares of Stock outstanding on the immediately preceding December 31, or such lesser number of shares as approved by the board of directors. The pool increased by 794,368 shares on January 1, 2023. As of March 31, 2023 , there were 2,516,734 options outstanding, including 150,000 options related to an employee inducement grant in November 2022 as well as the Exchanged Options, with a weighted-average exercise price of $ 1.62 and 487,473 shares available for future grants under the 2022 Plan. Shares underlying awards that are forfeited, cancelled, reacquired by the Company prior to vesting, satisfied without the issuance of common stock, or are otherwise terminated under the 2022 Plan without having been fully exercised (including the Exchanged Options) will be available for future awards. Stock Option Activity The following table summarizes the Company’s stock option activity for the three months ended March 31, 2023: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2022 2,152,641 $ 1.67 9.1 $ 748 Granted 372,600 1.30 Cancelled or forfeited ( 8,507 ) 0.59 Outstanding as of March 31, 2023 2,516,734 $ 1.62 9.0 $ 358 Exercisable as of March 31, 2023 557,606 $ 0.59 8.3 $ 171 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock. The weighted-average grant date fair value of options granted during the three months ended March 31, 2023 was $ 0.84 . As of March 31, 2023 , total unrecognized compensation cost related to the unvested stock options was $ 2.1 million, which is expected to be recognized over a weighted-average period of 3.2 years. Stock-Based Compensation Stock-based compensation expense was allocated as follows: Three Months Ended March 31, 2023 2022 Cost of revenue $ 1,883 $ 414 Research and development 4,941 3,798 General and administrative 293,941 38,344 Total stock-based compensation $ 300,765 $ 42,556

Common Stock Warrants

Common Stock Warrants	3 Months Ended
	Mar. 31, 2023
Warrants and Rights Note Disclosure [Abstract]
Common Stock Warrants	11. Common Stock Warrants During the three months ended March 31, 2023 , there were 4,812,484 warrants issued. There were no warrants exercised or expired. The following represents a summary of the warrants outstanding and exercisable at March 31, 2023: Number of Shares Underlying Warrants Description Issue Date Classification Exercise Price Expiration Date Outstanding Shares Exercisable Shares 2020 Private Placement Warrants Nov 17, 2020 Liability $ 11.50 May 19, 2027 5,817,757 5,817,757 Public Warrants Nov 17, 2020 Equity $ 11.50 May 19, 2027 5,223,575 5,223,575 January 2023 PIPE Warrants Jan 4, 2023 Equity $ 1.23 Jan 4, 2028 4,812,484 4,812,484 15,853,816 15,853,816 The following table summarizes warrant activity for the three months ended March 31, 2023: Number of Common Warrants Weighted Average Exercise Price Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of December 31, 2022 11,041,332 $ 11.50 4.38 $ — Warrants issued 4,812,484 $ 1.23 4.76 Outstanding as of March 31, 2023 15,853,816 $ 8.38 4.33 $ — The Company’s freestanding warrant instruments consist of private placement warrants to purchase shares of common stock (the “2020 Private Placement Warrants”) and public warrants to purchase shares of common stock (the “Public Warrants”) that were assumed as part of the Transaction. In addition, the Company issued the January 2023 PIPE Warrants in connection with the January 2023 PIPE. The January 2023 PIPE Warrants are considered freestanding instruments and are immediately exercisable for two shares of the Company's common stock at an exercise price of $ 1.23 per Warrant Share for an aggregate of 4,812,484 Warrant Shares. The January 2023 PIPE Warrants are indexed to the Company's common stock and meet the equity classification criteria.

Concentrations of Risk

Concentrations of Risk	3 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Concentrations of Risk	12. Concentrations of Risk The Company has certain customers whose revenue individually represented 10% or more of the Company’s total revenue or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable. For the three months ended March 31, 2023 and 2022 , one customer accounted for 100 % and two customers accounted for 95 % of revenue recognized in the period, respectively. There were no accounts receivables as of March 31, 2023 .

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The Company had no income tax expense due to operating losses incurred for the three months ended March 31, 2023 and 2022. Management of the Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. As a result, a full valuation allowance was recorded as of March 31, 2023. The Company applies ASC 740, Income Taxes , for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. Unrecognized tax benefits represent tax positions for which reserves have been established. A full valuation allowance has been provided against the Company’s deferred tax assets, so that the effect of the unrecognized tax benefits is to reduce the gross amount of the deferred tax asset and the corresponding valuation allowance. The Company has no material uncertain tax positions as of March 31, 2023 . The Company has never been examined by the Internal Revenue Service, or any other jurisdiction, for any tax years and, as such, all years within the applicable statutes of limitations are potentially subject to audit.

Net Loss per Share - Basic and

Net Loss per Share - Basic and Diluted	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss per Share - Basic and Diluted	14. Net Loss per Share – Basic and Diluted For the three months ended March 31, 2023 and 2022, basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares. Undistributed losses were allocated entirely to common stockholders since neither the convertible preferred stock nor the contingently returnable earn-out shares from the Transaction (the “Earn-Out Shares”) are required to share in the losses of the Company. For the three months ended March 31, 2023 and 2022, diluted net loss per share is the same as basic net loss per share since the effect of considering options to purchase common stock, warrants to purchase common stock, Earn-Out Shares, and convertible preferred stock in the calculation would be antidilutive. The following potentially dilutive common stock instruments presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share because including them would have had an antidilutive effect: Three Months Ended March 31, 2023 2022 Options to purchase common stock 2,516,734 1,902,643 Earn-Out Shares 3,150,000 — Convertible preferred stock (as converted to common stock) 342,754 10,643,403 Warrants to purchase common stock 15,853,816 — The following table sets forth the calculation of basic and diluted net loss per share: Three Months Ended March 31, 2023 2022 Net loss available to common stockholders — basic and diluted $ ( 2,568,128 ) $ ( 2,879,395 ) Weighted-average number of common shares used in 19,033,436 718,419 Net loss per share attributable to common $ ( 0.13 ) $ ( 4.01 )

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Leases On March 8, 2018, the Company entered into a non-cancelable operating lease agreement for office and laboratory space in Woburn, Massachusetts. On March 10, 2021, the Company extended the lease agreement through June 30, 2024 with monthly payments of $ 12 thousand, subject to annual increases in January based on changes in the consumer price index. On March 4, 2022, the Company executed the first amendment to the Woburn Lease (the “Amendment”) which increased the size of the leased office and laboratory space with aggregate monthly payments of $ 18 thousand, subject to annual increases based on the consumer price index , in addition to payment of a proportional share of operating costs. The maturities and balance sheet presentation under all non-cancelable operating leases as of March 31, 2023, are as follows: Operating Leases Maturity of lease liabilities 2023 $ 163,159 2024 123,077 Total lease liabilities 286,236 Less imputed interest ( 15,067 ) Present value of operating lease liability as of March 31, 2023 $ 271,169 Reported as of March 31, 2023 Lease liabilities — current $ 217,500 Lease liabilities — noncurrent 53,669 $ 271,169 As the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at each lease commencement date in determining the present value of the lease payments. The weighted-average discount rate used for leases as of March 31, 2023 is 8.0 %. The weighted-average lease term as of March 31, 2023 is 1.3 years. During the three months ended March 31, 2023 and 2022 operating cash flows used for operating leases was $ 54 thousand and $ 36 thousand, respectively. During the three months ended March 31, 2023 and 2022 , lease cost was $ 56 thousand and $ 35 thousand, respectively. Amounts included in restricted cash as of March 31, 2023 and December 31, 2022 included $ 50 thousand held to collateralize a letter of credit issued as a security deposit in connection with the Company’s lease of its corporate facility and for certain credit cards. Legal Proceedings The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of March 31, 2023, and, to the best of the Company’s knowledge, no material legal proceedings are currently pending or threatened. Indemnification Agreements The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third-party with respect to the Company’s products. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. In addition, the Company maintains officers and directors insurance coverage. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Through March 31, 2023 , the Company had no t experienced any losses related to these indemnification agreements and no material claims were outstanding.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The condensed consolidated financial statements do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s consolidated financial statements and related notes for the years ended December 31, 2022 and 2021 included in the Form 10-K filed with the SEC on March 17, 2023 (the “2022 Annual Report”). The financial information as of March 31, 2023, and for the three months ended March 31, 2023 and 2022, is unaudited. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for the fair presentation of financial position, results of operations, and cash flows at the dates and for the periods presented, have been included. The balance sheet data as of December 31, 2022 was derived from audited consolidated financial statements. The results of the Company’s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Significant discovery, research and development efforts, including clinical testing and regulatory approval, are required prior to commercialization of any potential product candidates. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. Through March 31, 2023, the Company has funded its operations primarily with proceeds from the issuance of equity instruments and convertible notes. The Company has incurred recurring losses since its inception, including a net loss of $ 2.5 million and $ 2.9 million for the three months ended March 31, 2023 and 2022, respectively. In addition, as of March 31, 2023, the Company had an accumulated deficit of $ 37.4 million . The Company expects to continue to generate operating losses for the near future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company does not believe the cash, cash equivalents, and restricted cash on hand as of March 31, 2023 of $ 1.6 million will be sufficient to fund its operations and capital expenditure requirements for the next twelve months from the date the condensed consolidated financial statements are issued. The Company will be required to raise additional capital to continue to fund its operations. Such funding may not be available on acceptable terms, or at all. If the Company is unable to access additional funds when needed, it may not be able to continue operations or the Company may be required to delay, scale back or eliminate some or all of its ongoing research and development efforts and other operations. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm its business, financial condition and results of operations. These uncertainties create substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of derivative warrant liabilities, valuation of earn-out shares, and revenue recognition. Changes in estimates are recorded in the period in which they become known. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The significant accounting policies of the Company are set forth in Note 2, Basis of Presentation and Significant Accounting Policies , of the consolidated financial statements included in the 2022 Annual Report. During the three months ended March 31, 2023, the Company did not make any changes to its significant accounting policies.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements and disclosures.

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value Hierarchy for Liabilities, Measured at Fair Value on a Recurring Basis	The following table presents the Company’s fair value hierarchy for its liabilities, which are measured at fair value on a recurring basis as of March 31, 2023: Fair Value Measurements at March 31, 2023 Using: Level 1 Level 2 Level 3 Total Liabilities: Derivative warrant liabilities $ — $ 250,745 $ — $ 250,745 Fair Value Measurements at December 31, 2022 Using: Level 1 Level 2 Level 3 Total Liabilities: Derivative warrant liabilities $ — $ 277,507 $ — $ 277,507

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Summary of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: March 31, December 31, Prepaid insurance $ 535,098 $ 913,611 Contract assets 248,635 — Other 85,051 72,888 Prepaid expenses and other current assets $ 868,784 $ 986,499

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following: March 31, December 31, Lab equipment $ 676,010 $ 587,650 Leasehold improvements 36,149 36,149 Computer equipment 35,002 32,178 Other equipment 9,411 9,411 Construction in progress 2,825 88,359 759,397 753,747 Less accumulated depreciation ( 524,821 ) ( 496,561 ) Property and equipment, net $ 234,576 $ 257,186

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: March 31, December 31, Accrued bonus $ 882,485 $ 767,093 Professional fees 274,766 282,454 Accrued vacation 30,814 21,194 Other 177,269 225,023 Accrued expenses and other current liabilities $ 1,365,334 $ 1,295,764

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2023
Temporary Equity Disclosure [Abstract]
Schedule of Convertible Preferred Stock	Convertible preferred stock consisted of the following as of March 31, 2023: Par Value Shares Authorized Shares Issued and Carrying Value Liquidation Common Stock Series A Preferred Stock $ 0.0001 4,305 4,305 $ 4,604,526 $ 4,604,526 342,754

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Schedule of common stock reserved for future issuance	As of March 31, 2023, the Company has reserved the following shares of common stock for future issuance: Exercise of outstanding stock options 2,516,734 Available for issuance under equity compensation plans 487,473 Exercise of outstanding common stock warrants 15,853,816 Conversion of Series A Preferred Stock 1,028,262 Reserved for issuance pursuant to the Arena Purchase Agreement 4,204,644 Total shares of authorized common stock reserved for future issuance 24,090,929
Schedule of Reconciliation of Gross Proceeds from PIPE to Cash Flows	The following table reconciles the gross proceeds received from the January 2023 PIPE to the statement of cash flows: Total gross proceeds 3,561,238 Advanced deposits received in FY22 ( 1,505,625 ) Non-cash proceeds related to board compensation ( 68,125 ) Issuance costs paid in cash ( 536 ) FY23 cash proceeds from January 2023 PIPE, net of issuance costs 1,986,952

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity for the three months ended March 31, 2023: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2022 2,152,641 $ 1.67 9.1 $ 748 Granted 372,600 1.30 Cancelled or forfeited ( 8,507 ) 0.59 Outstanding as of March 31, 2023 2,516,734 $ 1.62 9.0 $ 358 Exercisable as of March 31, 2023 557,606 $ 0.59 8.3 $ 171
Summary of Stock-based Compensation Expense	Stock-based compensation expense was allocated as follows: Three Months Ended March 31, 2023 2022 Cost of revenue $ 1,883 $ 414 Research and development 4,941 3,798 General and administrative 293,941 38,344 Total stock-based compensation $ 300,765 $ 42,556

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2023
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrants Outstanding and Exercisable	The following represents a summary of the warrants outstanding and exercisable at March 31, 2023: Number of Shares Underlying Warrants Description Issue Date Classification Exercise Price Expiration Date Outstanding Shares Exercisable Shares 2020 Private Placement Warrants Nov 17, 2020 Liability $ 11.50 May 19, 2027 5,817,757 5,817,757 Public Warrants Nov 17, 2020 Equity $ 11.50 May 19, 2027 5,223,575 5,223,575 January 2023 PIPE Warrants Jan 4, 2023 Equity $ 1.23 Jan 4, 2028 4,812,484 4,812,484 15,853,816 15,853,816
Summarizes Warrant Activity	The following table summarizes warrant activity for the three months ended March 31, 2023: Number of Common Warrants Weighted Average Exercise Price Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of December 31, 2022 11,041,332 $ 11.50 4.38 $ — Warrants issued 4,812,484 $ 1.23 4.76 Outstanding as of March 31, 2023 15,853,816 $ 8.38 4.33 $ —

Net Loss per Share - Basic an_2

Net Loss per Share - Basic and Diluted (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Potentially Dilutive Common Stock Instruments Excluded from Computation of Diluted Net Loss Per Share	The following potentially dilutive common stock instruments presented based on amounts outstanding at each period end, were excluded from the computation of diluted net loss per share because including them would have had an antidilutive effect: Three Months Ended March 31, 2023 2022 Options to purchase common stock 2,516,734 1,902,643 Earn-Out Shares 3,150,000 — Convertible preferred stock (as converted to common stock) 342,754 10,643,403 Warrants to purchase common stock 15,853,816 —
Schedule of Calculation of Basic and Diluted Net Loss Per Share	The following table sets forth the calculation of basic and diluted net loss per share: Three Months Ended March 31, 2023 2022 Net loss available to common stockholders — basic and diluted $ ( 2,568,128 ) $ ( 2,879,395 ) Weighted-average number of common shares used in 19,033,436 718,419 Net loss per share attributable to common $ ( 0.13 ) $ ( 4.01 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Summary of Maturities and Balance Sheet Presentation Under All Non-cancelable Operating Leases	The maturities and balance sheet presentation under all non-cancelable operating leases as of March 31, 2023, are as follows: Operating Leases Maturity of lease liabilities 2023 $ 163,159 2024 123,077 Total lease liabilities 286,236 Less imputed interest ( 15,067 ) Present value of operating lease liability as of March 31, 2023 $ 271,169 Reported as of March 31, 2023 Lease liabilities — current $ 217,500 Lease liabilities — noncurrent 53,669 $ 271,169

Organization - Additional Infor

Organization - Additional Information (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Date of Incorporation	Jan. 25, 2022
OTR Acquisition Corp
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Date of acquisition	May 19, 2022
Reverse Recapitalization Transaction
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Goodwill recorded	$ 0
Intangible assets recorded	$ 0

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Product Information [Line Items]
Net loss	$ 2,481,312	$ 2,879,395
Accumulated deficit	37,385,235		$ 34,903,923
Cash and cash equivalents on hand	1,538,653	3,863,101	446,607
Cash, cash equivalents and restricted cash on hand	$ 1,588,653	$ 3,913,101	$ 2,002,232	$ 6,560,140
Common stock, par value	$ 0.0001		$ 0.0001

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities - Schedule of Fair Value Hierarchy for Liabilities, Measured at Fair Value on a Recurring Basis (Details) - Recurring - Derivative Warrant Liabilities - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	$ 250,745	$ 277,507
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	$ 250,745	$ 277,507

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 535,098	$ 913,611
Contract assets	248,635
Other	85,051	72,888
Prepaid expenses and other current assets	$ 868,784	$ 986,499

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 759,397	$ 753,747
Less accumulated depreciation	(524,821)	(496,561)
Property and equipment, net	234,576	257,186
Lab Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	676,010	587,650
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	36,149	36,149
Computer Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	35,002	32,178
Other Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	9,411	9,411
Construction In Progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,825	$ 88,359

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 28,260	$ 24,774

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued bonus	$ 882,485	$ 767,093
Professional fees	274,766	282,454
Accrued vacation	30,814	21,194
Other	177,269	225,023
Accrued expenses and other current liabilities	$ 1,365,334	$ 1,295,764

Insurance Premium Financing (Ad

Insurance Premium Financing (Additional Information) (Details) - USD ($)	1 Months Ended
	May 31, 2022	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Outstanding balance			$ 455,562
Finance Agreement | First Insurance Funding
Debt Instrument [Line Items]
Amount financed	$ 1,500,000
Interest rate	4%
Frequency of periodic payment	monthly
Monthly payment	$ 154,000
Maturity date	Mar. 31, 2023
Outstanding balance		$ 0

Legacy Comera Convertible Pre_2

Legacy Comera Convertible Preferred Stock - Additional Information (Details) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, par value	$ 0.0001
Series A Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized	4,305	4,305
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued	4,305	4,305

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	May 31, 2022	Mar. 31, 2023	Dec. 31, 2022
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized		1,000,000	1,000,000
Convertible preferred stock, par value		$ 0.0001
Issuance costs for convertible preferred stock		$ 536
Accretion of preferred stock considered as deemed dividend		$ 87,000
Series A Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares authorized		4,305	4,305
Convertible preferred stock, par value		$ 0.0001	$ 0.0001
Dividend payment terms, description		The holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to the declaration or payment of any dividend on any other currently-outstanding capital stock, dividends when, as and if declared by the board of directors, payable quarterly on January 1, April 1, July 1 and October 1 of each calendar year (each date a “Series A Quarterly Dividend Payment Date”), commencing on and including July 1, 2022, which dividends shall be paid in cash at a rate of 8.0% per annum on the Series A Original Purchase Price for the first six Series A Quarterly Dividend Payment Dates, which shall increase by 2% per annum from and after each successive Series A Quarterly Dividend Payment Date, up to a maximum of 18%.
Cumulative dividends in arrears		$ 300,000
Series A Preferred Stock | Transaction and Settlement Agreement
Temporary Equity [Line Items]
Convertible preferred stock, shares issued	4,305
Original purchase price	$ 1,000
Issuance costs for convertible preferred stock	$ 162,000
Series A Preferred Stock | Transaction and Settlement Agreement | Maxim Group LLC.
Temporary Equity [Line Items]
Advisory fees	$ 4,300,000

Convertible Preferred Stock - S

Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Temporary Equity [Line Items]
Par Value	$ 0.0001
Shares Authorized	1,000,000	1,000,000
Common Stock Issuable Upon Conversion	1,028,262
Series A Preferred Stock
Temporary Equity [Line Items]
Par Value	$ 0.0001	$ 0.0001
Shares Authorized	4,305	4,305
Shares Issued	4,305	4,305
Shares Outstanding	4,305	4,305
Carrying Value	$ 4,604,526	$ 4,517,710
Liquidation Preference	$ 4,604,526
Common Stock Issuable Upon Conversion	342,754

Common Stock (Additional Inform

Common Stock (Additional Information) (Details) - USD ($)				3 Months Ended	12 Months Ended
	Jan. 04, 2023	Jan. 02, 2023	Aug. 31, 2022	Mar. 31, 2023	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of common stock				$ 49,158
Deferred offering costs paid in cash				$ 536
Common stock, shares authorized				150,000,000	150,000,000
Common stock, par value				$ 0.0001	$ 0.0001
Each common stock entitles voting right				one vote
Cash dividends				$ 0
Excercise price of warrants				$ 8.38	$ 11.50
Proceeds From Advance Deposits					$ 1,505,625
Purchase Agreement | Arena Business Solutions Global SPC II, Ltd. | Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of common stock sold				37,230
Proceeds from issuance of common stock				$ 49,000
Additional commitment amount			$ 30,000,000
Percentage of purchase price of shares equal to simple average of the daily VWAP			96%
Commitment shares			296,181
Fair value of commitment shares			$ 650,000
Other issuance costs			379,000
Weighted-average price				$ 1.32
Purchase Agreement | Arena Business Solutions Global SPC II, Ltd. | Common Stock | Maximum
Subsidiary, Sale of Stock [Line Items]
Commitment amount			15,000,000
Obligated purchase amount			$ 15,000,000
2023 PIPE Purchase Agreement
Subsidiary, Sale of Stock [Line Items]
Net proceeds from issuance of common stock and warrants	$ 3,200,000
Deferred offering costs paid in cash				$ 361,000
Units issued		2,406,242
Price per unit		$ 1.48
2023 Private Placement Warrant
Subsidiary, Sale of Stock [Line Items]
Excercise price of warrants		$ 1.23
Issuance of common stock and warrants in connection with common stock purchase agreement		$ 3,600,000
Price per unit		$ 0.25

Common Stock - Schedule of Comm

Common Stock - Schedule of Common Stock Reserved for Future Issuance (Details) - shares	Mar. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Exercise of outstanding stock options	2,516,734	2,152,641
Available for issuance under equity compensation plans	487,473
Exercise of outstanding common stock warrants	15,853,816	11,041,332
Conversion of Series A Preferred Stock	1,028,262
Reserved for issuance pursuant to the Arena Purchase Agreement	4,204,644
Common Stock, Capital Shares Reserved for Future Issuance, Total	24,090,929

Common Stock - Schedule of Reco

Common Stock - Schedule of Reconciliation of Gross Proceeds from PIPE to Cash Flows (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Proceeds from Issuance or Sale of Equity [Abstract]
Total gross proceeds	$ 3,561,238
Advanced deposits received in FY22		$ (1,505,625)
Non-cash proceeds related to board compensation	(68,125)
Issuance costs paid in cash	(536)
Proceeds from Issuance of Private Placement, Total	$ 1,986,952

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2023	Jan. 01, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, exercisable	557,606
Shares exercisable, weighted-average exercise price	$ 0.59
Number of options outstanding	2,516,734		2,152,641
Options outstanding, weighted-average exercise price	$ 1.62		$ 1.67
Shares available for future grant	487,473
Weighted-average grant date fair value of options granted	$ 0.84
Unrecognized compensation cost	$ 2.1
Unrecognized compensation cost related to non-vested awards, expected period	3 years 2 months 12 days
2021 Stock option and Grant Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, exercisable	1,159,934
Shares exercisable, weighted-average exercise price	$ 0.59
Number of options outstanding	2,516,734
Number of exchanged options	1,159,934
2022 Equity and Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized for issuance	2,059,838
Percentage of increase in shares of stock outstanding	4%
Number of shares increased		794,368
Number of options outstanding	2,516,734
Options outstanding, weighted-average exercise price	$ 1.62
Shares available for future grant	487,473
2022 Equity and Incentive Plan | Employee Inducement Grant November 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding	150,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Number of options, Outstanding beginning balance	2,152,641
Number of options, Granted	372,600
Number of options, Cancelled or forfeited	(8,507)
Number of options, Outstanding ending balance	2,516,734	2,152,641
Number of options, Exercisable	557,606
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-average exercise price, Outstanding beginning balance	$ 1.67
Weighted-average exercise price, Granted	1.30
Weighted-average exercise price, Cancelled or forfeited	0.59
Weighted-average exercise price, Outstanding ending balance	1.62	$ 1.67
Weighted-average exercise price, Exercisable	$ 0.59
Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]
Weighted-average remaining contractual term (years), Outstanding	9 years	9 years 1 month 6 days
Weighted-average remaining contractual term (years), Exercisable	8 years 3 months 18 days
Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]
Aggregate intrinsic value, Outstanding beginning balance	$ 748
Aggregate intrinsic value, Outstanding ending balance	358	$ 748
Aggregate intrinsic value, Exercisable	$ 171

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-based compensation expense
Stock-based compensation expense	$ 300,765	$ 42,556
Cost of Revenue
Stock-based compensation expense
Stock-based compensation expense	1,883	414
Research and Development
Stock-based compensation expense
Stock-based compensation expense	4,941	3,798
General and Administrative
Stock-based compensation expense
Stock-based compensation expense	$ 293,941	$ 38,344

Common Stock Warrants - Additio

Common Stock Warrants - Additional Information (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Warrants issued	4,812,484
Warrants exercised	0
Warrants expired	0
Excercise price of warrants	$ 8.38	$ 11.50
January 2023 PIPE Warrants
Class of Warrant or Right [Line Items]
Number of securities called by each warrant or right	2
Excercise price of warrants	$ 1.23
Number of warrants (in shares)	4,812,484

Common Stock Warrants - Summary

Common Stock Warrants - Summary of Warrants Outstanding and Exercisable (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Exercise Price	$ 8.38	$ 11.50
Number of Shares Underlying Warrants, Outstanding Shares	15,853,816	11,041,332
Number of Shares Underlying Warrants, Exercisable Shares	15,853,816
2020 Private Placement Warrants
Class of Warrant or Right [Line Items]
Issue Date	Nov. 17, 2020
Classification	Liability
Exercise Price	$ 11.50
Expiration Date	May 19, 2027
Number of Shares Underlying Warrants, Outstanding Shares	5,817,757
Number of Shares Underlying Warrants, Exercisable Shares	5,817,757
Public Warrants
Class of Warrant or Right [Line Items]
Issue Date	Nov. 17, 2020
Classification	Equity
Exercise Price	$ 11.50
Expiration Date	May 19, 2027
Number of Shares Underlying Warrants, Outstanding Shares	5,223,575
Number of Shares Underlying Warrants, Exercisable Shares	5,223,575
January 2023 PIPE Warrants
Class of Warrant or Right [Line Items]
Issue Date	Jan. 04, 2023
Classification	Equity
Exercise Price	$ 1.23
Expiration Date	Jan. 04, 2028
Number of Shares Underlying Warrants, Outstanding Shares	4,812,484
Number of Shares Underlying Warrants, Exercisable Shares	4,812,484

Common Stock Warrants - Summari

Common Stock Warrants - Summarizes Warrant Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Warrants and Rights Note Disclosure [Abstract]
Number of Common Warrants, Outstanding, beginning balance	11,041,332
Number of Common Warrants, issued	4,812,484
Number of Common Warrants, Outstanding, ending balance	15,853,816	11,041,332
Weighted Average Exercise Price, Outstanding beginning balance	$ 11.50
Weighted Average Exercise Price	1.23
Weighted Average Exercise Price, Outstanding ending balance	$ 8.38	$ 11.50
Average Remaining Contractual Term (Years), Outstanding	4 years 3 months 29 days	4 years 4 months 17 days
Average Remaining Contractual Term (Years), Warrants issued	4 years 9 months 3 days

Concentrations of Risk (Additio

Concentrations of Risk (Additional Information) (Details) - Customer Concentration Risk - Customer - Customer	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounts Receivable
Concentration Risk [Line Items]
Concentration risk	0%
Revenue
Concentration Risk [Line Items]
Concentration risk	100%	95%
Number of customer	1	2

Income Taxes (Additional Inform

Income Taxes (Additional Information) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0

Net Loss per Share - Basic an_3

Net Loss per Share - Basic and Diluted - Schedule of Potentially Dilutive Common Stock Instruments Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	3,150,000
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,516,734	1,902,643
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	342,754	10,643,403
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	15,853,816

Net Loss per Share - Basic an_4

Net Loss per Share - Basic and Diluted - Schedule of Calculation of Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Net loss available to common stockholders - basic and diluted	$ (2,568,128)	$ (2,879,395)
Weighted-average number of common shares used in computing net loss per share attributable to common stockholders - basic	19,033,436	718,419
Weighted-average number of common shares used in computing net loss per share attributable to common stockholders - diluted	19,033,436	718,419
Net loss per share attributable to common stockholders - basic	$ (0.13)	$ (4.01)
Net loss per share attributable to common stockholders - diluted	$ (0.13)	$ (4.01)

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)			1 Months Ended	3 Months Ended
	Mar. 04, 2022	Mar. 10, 2021	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Loss Contingencies [Line Items]
Operating lease, weighted average discount rate			8%	8%
Operating lease, weighted average lease term			1 year 3 months 18 days	1 year 3 months 18 days
Operating cash flows used for operating leases				$ 54,000	$ 36,000
Lease cost				56,000	$ 35,000
Losses on indemnification agreement			$ 0
Held to Collateral of letter of credit			$ 50,000	$ 50,000		$ 50,000
Woburn, Massachusetts
Loss Contingencies [Line Items]
Lessee, operating lease, option to extend				On March 10, 2021, the Company extended the lease agreement through June 30, 2024 with monthly payments of $12 thousand, subject to annual increases in January based on changes in the consumer price index. On March 4, 2022, the Company executed the first amendment to the Woburn Lease (the “Amendment”) which increased the size of the leased office and laboratory space with aggregate monthly payments of $18 thousand, subject to annual increases based on the consumer price index
Lessee, operating lease, existence of option to extend [true false]		true
Lease expiration date		Jun. 30, 2024
Lease payments	$ 18,000	$ 12,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Maturities and Balance Sheet Presentation Under All Non-cancelable Operating Leases (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Maturity of lease liabilities
2023	$ 163,159
2024	123,077
Total lease liabilities	286,236
Less imputed interest	(15,067)
Present value of operating lease liability as of March 31, 2023	271,169
Lease liabilities - current	217,500	$ 199,184
Lease liabilities - noncurrent	53,669	$ 120,302
Operating lease liability	$ 271,169